These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. SARS-CoV-2 inactivation in laboratory animal tissues with 4% formaldehyde or 5% glutaraldehyde for transfer to biosafety level 1 laboratories. Pilchová V; Elmontaser Mergani A; Clever S; Ciurkiewicz M; Becker K; Gerhauser I; Baumgärtner W; Volz A; von Köckritz-Blickwede M; Schulz C Vet Pathol; 2024 Mar; 61(2):201-206. PubMed ID: 37698272 [TBL] [Abstract][Full Text] [Related]
6. An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. Li D; Chen T; Hu Y; Zhou Y; Liu Q; Zhou D; Jin X; Huang Z J Virol; 2016 Oct; 90(19):8720-8. PubMed ID: 27440895 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. Widera M; Westhaus S; Rabenau HF; Hoehl S; Bojkova D; Cinatl J; Ciesek S Med Microbiol Immunol; 2021 Aug; 210(4):235-244. PubMed ID: 34196781 [TBL] [Abstract][Full Text] [Related]
8. Infectious viruses from transfected SARS-CoV-2 genomic RNA. Väisänen E; Jiang M; Laine L; Waris M; Julkunen I; Österlund P Front Bioeng Biotechnol; 2023; 11():1129111. PubMed ID: 37064222 [TBL] [Abstract][Full Text] [Related]
9. Inactivation of Material from SARS-CoV-2-Infected Primary Airway Epithelial Cell Cultures. Barrow KA; Rich LM; Vanderwall ER; Reeves SR; Rathe JA; White MP; Debley JS Methods Protoc; 2021 Jan; 4(1):. PubMed ID: 33430421 [TBL] [Abstract][Full Text] [Related]
10. The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples. Burton JE; Easterbrook L; Pitman J; Anderson D; Roddy S; Bailey D; Vipond R; Bruce CB; Roberts AD J Virol Methods; 2017 Dec; 250():34-40. PubMed ID: 28941617 [TBL] [Abstract][Full Text] [Related]
11. Development of a New Reverse Genetics System for Ebola Virus. Gan T; Zhou D; Huang Y; Xiao S; Ma Z; Hu X; Tong Y; Yan H; Zhong J mSphere; 2021 May; 6(3):. PubMed ID: 33952663 [TBL] [Abstract][Full Text] [Related]
12. Assessment of inactivation procedures for SARS-CoV-2. Auerswald H; Yann S; Dul S; In S; Dussart P; Martin NJ; Karlsson EA; Garcia-Rivera JA J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416462 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies. Eddins DJ; Bassit LC; Chandler JD; Haddad NS; Musall KL; Yang J; Kosters A; Dobosh BS; Hernández MR; Ramonell RP; Tirouvanziam RM; Lee FE; Zandi K; Schinazi RF; Ghosn EEB Immunohorizons; 2022 Feb; 6(2):144-155. PubMed ID: 35173021 [TBL] [Abstract][Full Text] [Related]
14. Art of the Kill: Designing and Testing Viral Inactivation Procedures for Highly Pathogenic Negative Sense RNA Viruses. Olejnik J; Hume AJ; Ross SJ; Scoon WA; Seitz S; White MR; Slutzky B; Yun NE; Mühlberger E Pathogens; 2023 Jul; 12(7):. PubMed ID: 37513799 [TBL] [Abstract][Full Text] [Related]